Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
38.9M
-
Shares change
-
+4M
-
Total reported value, excl. options
-
$151M
-
Value change
-
+$14.6M
-
Put/Call ratio
-
0.71
-
Number of buys
-
66
-
Number of sells
-
-40
-
Price
-
$3.89
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q4 2021
153 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q4 2021.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.9M shares
of 193M outstanding shares and own 20.13% of the company stock.
Largest 10 shareholders include BlackRock Inc. (6.17M shares), VANGUARD GROUP INC (4.56M shares), MILLENNIUM MANAGEMENT LLC (3.04M shares), RTW INVESTMENTS, LP (2.5M shares), Nuveen Asset Management, LLC (2.01M shares), Hudson Bay Capital Management LP (1.81M shares), STATE STREET CORP (1.68M shares), GEODE CAPITAL MANAGEMENT, LLC (1.67M shares), ADVISOR GROUP HOLDINGS, INC. (1.36M shares), and BROOKFIELD ASSET MANAGEMENT INC. (1.19M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.